A simple, rapid, accurate and precise HPLC method was developed and validated for the simultaneous quantification of prifinium bromide and paracetamol combination in pharmaceutical dosage form. The separation was achieved on a normal phase-nitrile (CN) column. The mobile phase consisted of 30 mM ammonium acetate buffer-acetonirtile (50%:50%, v/v) at pH = 6.5.
Introduction
Fixed-dose combination (FDC) drugs are pharmaceutical formulations containing two or more drugs in a single pill. [1] FDC drugs have been the area of intense research and development in recent years due to the reduction in manufacturing cost and to the increase in the patient adherence to such drugs in comparison to single component drugs. [2] Riabal ® Compound, which is a binary FDC drug, is formulated to contain prifinium bromide (PRF) and paracetamol (PAR). PRF is used as anticholinergic to treat gastro-intestinal, biliary and urinary tracts. PAR is used as a pain reliever and a fever reducer (Fig. 1 ). The quantitative analysis of PRF is carried out individually in pharmaceutical formulations by means of RP-HPLC-UV, [4] as well as in human serum and urine by NP-HPLC-UV [5] and UV-spectrophotometry. [6] The quantification of PAR either individually or in combination with other pharmaceutical ingredients has been carried out by HPLC, [7] LC-mass spectrometry, [8] voltammetry, [9] electrophoresis [10] and UV-derivative spectroscopy. [11] However, the simultaneous determination of PRF in combination with PAR has not been reported in the pharmaceutical and scientific literature to the date of this manuscript. The objective of this work is to develop and validate a rapid, sensitive,
accurate, and precise HPLC method to simultaneously quantify PRF and PAR in pharmaceutical dosage form, which could be applied in a routine drug quality control.
Experimental

Instrument and Chromatographic Conditions
An integrated HPLC system from Shimadzu Corporation (Chromatographic and Spectrophotometric Division, Kyoto, Japan) was used. The system consists of a liquid The analysis of PRF/PAR was carried out at a flow rate of 1.0 mL/min. The detection wavelength was 254 nm. The total analysis time was 10 minutes. The mobile phase was 30 mM ammonium acetate buffer-acetonirtile (50%:50%, v/v), pH = 6.5.
The mobile phase was degassed and filtered through a 0.2 μm filter paper prior to use.
Materials, Chemicals and Reagents
All stock solutions, working solutions and mobile phase solution were prepared using doubly distilled water. All reagents and chemicals were of analytical grade unless otherwise stated. Ammonium acetate (96%) was purchased from Avonchem (UK).
Glacial acetic acid was purchased from Merck (Darmstadt, Germany 
Preparation of Standards
Stock solutions (500 μg/mL) of each PRF and PAR were prepared in water using 25 mL volumetric flasks. To construct the calibration curve, appropriate aliquots from the stock solution were taken into a 10 mL volumetric flask and diluted to the mark with water. The working solutions were 3, 5, 10, 20, 30, 40 and 50 μg/mL for both PRF and PAR.
The stock of Riabal ® Compound was prepared by crushing three tablets to powder. The accurately weighed powder (0.18627 g) was transferred to a 25 mL volumetric flask and dissolved in the mobile phase to prepare 360 μg/mL PRF and 3900 μg/mL PAR (stock). The stock solutions was sonicated for 10 minutes and filtered using a 0.20 μm filter paper to remove insoluble excipients. A sample of 0.120 mL of the stock solution was transferred to a 10 mL volumetric flask to prepare 4.3 μg/mL PRF and 46.8 μg/mL PAR. The stock and working solutions were kept in refrigerator.
Similar procedure was carried out to assess the specificity and accuracy of the developed method using a mixture of the placebo powder with PRF and PAR reference standards.
Quantitative analysis was performed using the external standard method. 
Results and Discussion
HPLC Method Development
Detailed method development is presented due to the lack of a recent HPLC method for PRF and to clarify its behavior under different HPLC conditions, thus future analysis of PRF with other drug combinations could be rapidly attained. For the separation and quantification of PRF and PAR, a variety of mobile phase compositions and column types have been investigated.
Initially, The conditions reported by Sa'saa et al. have been adopted for the analysis of PRF. [4] The mobile phase consisted of ammonium acetate bufferacetonitrile (35%:65%, v/v) at pH = 4, the flow rate was 1.5 mL/min. The separation was carried out using a RP-C8 column and the detection wavelength was 254 nm.
Applying such conditions has resulted in eluting PRF at 21.7 min, Fig. 2b . In addition, the PRF signal is broad, asymmetrical and weak, inset of Fig. 2b . The elution time and the behavior of PRF on RP-C18 column was found identical to that on RP-C8 column.
The high retention time of PRF is expected in light of its high hydrophobicity, Fig.1 . In contrast, the PAR signal is sharp and eluted rapidly at 2.5 min, Fig. 2a . The aforementioned elution behavior of PRF on revered phase columns is not adequate for a rapid and sensitive analytical method. Thus, a switch to an organic normal stationary phase (ONP) column was carried out using a nitrile (CN) column.
Ammonium acetate buffer-to-acetonirtile ratio was adjusted to 50%:50% (v/v) at pH = 4. The mobile phase flowed at a rate of 1 mL/min. Under these chromatographic conditions, PRF was eluted at 2.8 min and the peak broadening exists no longer, Fig.   3b . Furthermore, the sensitivity of PRF was enhanced as evidenced by the large increase in its peak area. The latter chromatographic conditions have also reduced the retention time of PAR from 2.5 to 1.8 min with peak shape and sensitivity not changing significantly, Fig. 3a . Although the elution time of PAR coincides with the response of solution front, its effect was found negligible since the solution front response was very small in comparison to the PAR response. This result was confirmed by evaluating the relative standard deviation (%R.S.D.) of the peak area for the lower limit of quantification of PAR (1.6 μg/mL) and it was found to be lower than 1.2% (n = 10).
HPLC Method Validation
The optimized chromatographic conditions presented earlier were validated by evaluating the criteria of linearity, detection and quantification limits, specificity, accuracy, precision and robustness in accordance with the ICH guidelines Q2(R1). [12] Linearity Standard stock solution of PRF and PAR (500 μg/mL) was used to prepare the [12]
Limit of detection (LOD) and limit of quantification (LOQ)
The determination of LOD and LOQ is based on the slope and standard deviation of the y-intercept which are obtained from the linear calibration curve of each component. [12] LOD and LOQ for PRF were found to be 0.75 μg/mL and 2.30 μg/mL, respectively. LOD and LOQ for PAR were found to be 0.64 μg/mL and 1.60 μg/mL, respectively.
Specificity
The specificity of the method was determined by studying the interferences of the placebo components (see experimental) together with PRF and PAR compounds.
The developed HPLC method unequivocally assesses the PRF and PAR mixture in the presence of tablet (placebo) excipients. [12] 
Accuracy
The accuracy of the method was assessed from the recovery results of quality control (QC) samples of PRF and PAR. They were prepared by spiking the appropriate volume of stock to mobile phase containing placebo powder. The QC samples were chosen at three levels: 6, 24, and 42 μg/mL. The QC samples cover the entire calibration curve and were injected in triplicates, 
Precision
The precision of the method, as intra-day repeatability, was obtained from the QC samples of PRF and PAR prepared individually in mobile phase. The QC samples were injected nine times, Table 2 . The inter-day precision of the method was studied by analyzing the QC samples in triplicate on three different days under the same conditions, Table 3 . The %R.S.D. values measured during assessment of the intra-day and inter-day precision were less than 2.0% for both drugs, therefore, confirming that the method is precise.
[12] 
Robustness
Robustness is the method capacity to remain unaffected by small variations in the method parameters. The robustness of the developed method was studied by deliberately varying the pH (±0.2 units), the mobile phase composition (±2% acetonitrile) and the flow rate (±0.2 mL/min). [12] The effect of varying these parameters on the response to 20 μg/mL standard of each PRF and PAR was followed and the results are listed in Table 4 . The recovery results of the 20 μg/mL standard are within the limits allowed by the ICH guidelines, [12] which indicates that the developed method is not significantly affected by small variations in pH, mobile phase composition or flow rate. 
Simultaneous determination of PRF and PAR in mixture
The suitability of the validated method for the simultaneous quantification of PRF and PAR mixture was examined using laboratory prepared mixtures. The spiked binary mixtures were prepared in mobile phase at various proportions and were injected in triplicates, Table 5 . Under the proposed chromatographic conditions, PRF and PAR were completely separated, Fig. 5 . This indicates that the validated method could be used for the simultaneous identification of PRF and PAR drugs. Furthermore, the recovery results, which are within the permissible limits of the ICH guidelines, [12] strongly confirm that the developed method originally used to quantify PRF and PAR individually is valid and accurate to quantify both drugs in their mixture, Table 5 . 
Conclusions
This work addresses the challenges associated with the simultaneous quantification of PRF and PAR combination. These challenges are: (i) the extreme polarity difference between PRF and PAR which makes their separation rather not straight forward. (ii) The weak absorptivity coefficient of PRF, in addition to (iii) the PRF low content in drug tablet which strongly demand highly sensitive method to simultaneously detect both drugs. The developed HPLC method proved to be simple, specific, accurate, precise, sensitive and robust. It was applied successfully for the analysis of PRF and PAR in a combined dosage form without any interference from the excipients. This HPLC method might be useful for future extension to quantify this FDC drug in other formulations or in biological media such as urine, saliva and blood plasma.
